17 results
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
research and development efforts, to hire the appropriate personnel necessary to execute on those priorities, to incentivize critical talent, and to operate
PREM14A
ORTX
Orchard Therapeutics plc
3 Nov 23
Preliminary proxy related to merger
5:11pm
critical talent, and to operate generally as a public company, as well as the risks and uncertainties associated with conducting clinical trials and pre
DEFA14A
ORTX
Orchard Therapeutics plc
17 Oct 23
Additional proxy soliciting materials
4:32pm
talent throughout the business combination and beyond is a top priority of Kyowa Kirin to ensure the realisation of our shared vision.
Will Orchard … .
Will Orchard provide promotions and salary increases for 2023?
Yes. We will continue to operate our annual performance review and talent planning processes
DEFA14C
ORTX
Orchard Therapeutics plc
5 Oct 23
Additional information
4:43pm
has communicated Orchard’s people will be a central component of their gene therapy growth strategy. Consequently, retention of our talent throughout … promotions and salary increases for 2023?
Yes. We will continue to operate our annual performance review and talent planning processes. Year-end
DEF 14A
onklaubm6fm
29 Apr 20
Definitive proxy
4:02pm
PRE 14A
dcyi 62r8sym
14 Apr 20
Preliminary proxy
4:46pm
20-F
t86 sm99g
22 Mar 19
Annual report (foreign)
8:02am
6-K
EX-99.1
jc6acf7zzh
14 Dec 18
Orchard Therapeutics Announces theBuild-out of New Gene Therapy
4:16pm
424B4
xpt3tulsc4qrkd4
31 Oct 18
Prospectus supplement with pricing info
4:36pm
F-1/A
nzukfq qxus4i
23 Oct 18
Registration statement (foreign) (amended)
6:15am
F-1
s2jtx erni09ip
4 Oct 18
Registration statement (foreign)
4:48pm
DRS
by8mkk
6 Aug 18
Draft registration statement
12:00am
- Prev
- 1
- Next